Keio-born AdipoSeeds raises late-stage round from Toho, Kohjin Bio for platelet therapies
What's the deal? AdipoSeeds, a Keio University School of MedicineDealroom has a profile for this one. Try Dealroom → spinout, has closed a late-stage funding round through a third-party share allotment to Toho HoldingsDealroom has a profile for this one. Try Dealroom → and Kohjin BioDealroom has a profile for this one. Try Dealroom →. The Tokyo-based company develops ASCL-PLC, a multifunctional platelet-like cell derived from adipose tissue.
What does it do? Founded in July 2016, AdipoSeeds builds on research by Yumiko Matsubara, now a visiting professor at Keio's Institute for Integrated Sports Medicine. It runs two business lines: developing regenerative medicine products from human adipose-derived platelet-like cells, and services for platelet-rich plasma (PRP) therapy.
What's the money for? AdipoSeeds plans to begin domestic company-sponsored trials of ASCL-PLC and scale up its PRP business. Its lead pipeline, ADS-01, targets intractable skin ulcers and has been selected by Japan's Agency for Medical Research and Development (AMED) under a drug-discovery venture programme.
Who's backing it? Toho Holdings, a major pharmaceutical wholesaler, will help build a distribution network for regenerative medicine products using its nationwide logistics and temperature-control systems. Kohjin Bio, which makes cell-culture media and offers cell-processing services, signed a business partnership with AdipoSeeds on July 21, 2026, to jointly run PRP contract-processing for medical institutions.
Why PRP? PRP therapy treats cartilage and tendon damage, periodontal tissue, and skin regeneration using a patient's own concentrated platelets. It is valued for safety and minimal bodily damage, but platelet quality varies between people and over time, and preparation methods are not standardised across clinics.
The signal: The round pairs a research-stage biotech with two industrial partners — one for distribution, one for manufacturing — a structure that reflects how regenerative medicine ventures in Japan are moving from lab research toward commercial supply chains.
Read more: prtimes.jp
Image credit: pingnews.com
